Item | Resection group (n=20) | TACE group (n=20) | P value | Lesion number | | | 0.998 | <3 | 16 (80) | 16 (80) | | ≥3 | 4 (20) | 4 (20) | | Size of largest metastasis/cm | | | 0.908 | <5 | 12 (60) | 13 (65) | | ≥5 | 8 (40) | 7 (35) | | Pathological type | | | 0.999 | Undifferentiated | 20 (100) | 20 (100) | | Other types | 0 (0) | 0 (0) | | Dose of radiotherapy/Gy median (range) | | | 0.437 | Nasopharyngeal | 69 (66-74) | 70 (66-76) | | Regional lymph node | 65 (51-69) | 66 (52-71) | | Adjuvant chemotherapy cycles of NPC | | | 0.809 | <3 | 16 (80) | 15 (75) | | ≥3 | 4 (20) | 5 (25) | | Preoperative /pre-TACE complications | | | | Yes | 4 (20) | 4 (20) | 0.999 | No | 16 (80) | 16 (80) | | Postoperative/post-TACE complication | | | 0.607 | Yes | 3 (15) | 4 (20) | | No | 17 (85) | 16 (80) | | In-hospital mortality rate | 0 | 0 | 0.999 |
View table in article
表2
40例NCLM患者切除组与TACE组基线特征及治疗参数的对比分析
正文中引用本图/表的段落
32例(80%)患者肝脏病灶少于3个,15例(37.5%)患者肝脏病灶最大直径>5 cm。骨扫描、PET/CT及胸部X光或CT影像学检查未见骨、肺或其他肝外远处转移征象。两组原发肿瘤的治疗均包括放疗和辅助化疗。NPC治疗的中位放射剂量:切除组为69 Gy(66~74 Gy),TACE组为70 Gy(66~76 Gy)。区域淋巴结治疗的中位放射剂量:切除组为65 Gy(51~69 Gy),TACE组为66 Gy(52~71 Gy)。两组间差异无统计学意义(P>0.05,表2)。主要化疗方案为5-氟尿嘧啶(5-FU)联合顺铂或以这两种药物为基础的其他方案。此外,两组间辅助化疗的反应也无显著差异(表2)。同时性肝转移患者对原发肿瘤进行了同步放化疗。所有患者在放疗和化疗后均实现区域淋巴结和原发灶完全缓解。
本文的其它图/表
|